Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.

Wardell SE, Yllanes AP, Chao CA, Bae Y, Andreano KJ, Desautels TK, Heetderks KA, Blitzer JT, Norris JD, McDonnell DP.

Breast Cancer Res Treat. 2019 Nov 14. doi: 10.1007/s10549-019-05454-y. [Epub ahead of print]

PMID:
31562570
2.

Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models.

Manzari MT, Anderson GR, Lin KH, Soderquist RS, Çakir M, Zhang M, Moore CE, Skelton RN, Fèvre M, Li X, Bellucci JJ, Wardell SE, Costa SA, Wood KC, Chilkoti A.

Sci Adv. 2019 Sep 4;5(9):eaaw9162. doi: 10.1126/sciadv.aaw9162. eCollection 2019 Sep.

3.

Targeting mutant estrogen receptors.

Wardell SE, Norris JD, McDonnell DP.

Elife. 2019 Jan 16;8. pii: e44181. doi: 10.7554/eLife.44181.

4.

Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors.

Anderson GR, Wardell SE, Cakir M, Yip C, Ahn YR, Ali M, Yllanes AP, Chao CA, McDonnell DP, Wood KC.

Nat Commun. 2018 Apr 26;9(1):1677. doi: 10.1038/s41467-018-04033-x.

5.

Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.

McLeod AB, Stice JP, Wardell SE, Alley HM, Chang CY, McDonnell DP.

Prostate. 2018 Mar;78(4):266-277. doi: 10.1002/pros.23467. Epub 2017 Dec 15.

PMID:
29243324
6.

The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells.

Baek AE, Yu YA, He S, Wardell SE, Chang CY, Kwon S, Pillai RV, McDowell HB, Thompson JW, Dubois LG, Sullivan PM, Kemper JK, Gunn MD, McDonnell DP, Nelson ER.

Nat Commun. 2017 Oct 11;8(1):864. doi: 10.1038/s41467-017-00910-z.

7.

A Predictive Model for Selective Targeting of the Warburg Effect through GAPDH Inhibition with a Natural Product.

Liberti MV, Dai Z, Wardell SE, Baccile JA, Liu X, Gao X, Baldi R, Mehrmohamadi M, Johnson MO, Madhukar NS, Shestov AA, Chio IIC, Elemento O, Rathmell JC, Schroeder FC, McDonnell DP, Locasale JW.

Cell Metab. 2017 Oct 3;26(4):648-659.e8. doi: 10.1016/j.cmet.2017.08.017. Epub 2017 Sep 14.

8.

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.

Anderson GR, Winter PS, Lin KH, Nussbaum DP, Cakir M, Stein EM, Soderquist RS, Crawford L, Leeds JC, Newcomb R, Stepp P, Yip C, Wardell SE, Tingley JP, Ali M, Xu M, Ryan M, McCall SJ, McRee AJ, Counter CM, Der CJ, Wood KC.

Cell Rep. 2017 Jul 25;20(4):999-1015. doi: 10.1016/j.celrep.2017.07.006.

9.

Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.

Norris JD, Ellison SJ, Baker JG, Stagg DB, Wardell SE, Park S, Alley HM, Baldi RM, Yllanes A, Andreano KJ, Stice JP, Lawrence SA, Eisner JR, Price DK, Moore WR, Figg WD, McDonnell DP.

J Clin Invest. 2017 Jun 1;127(6):2326-2338. doi: 10.1172/JCI87328. Epub 2017 May 2.

10.

CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC.

Stice JP, Wardell SE, Norris JD, Yllanes AP, Alley HM, Haney VO, White HS, Safi R, Winter PS, Cocce KJ, Kishton RJ, Lawrence SA, Strum JC, McDonnell DP.

Mol Cancer Res. 2017 Jun;15(6):660-669. doi: 10.1158/1541-7786.MCR-17-0028. Epub 2017 Feb 16.

11.

PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.

Anderson GR, Wardell SE, Cakir M, Crawford L, Leeds JC, Nussbaum DP, Shankar PS, Soderquist RS, Stein EM, Tingley JP, Winter PS, Zieser-Misenheimer EK, Alley HM, Yllanes A, Haney V, Blackwell KL, McCall SJ, McDonnell DP, Wood KC.

Sci Transl Med. 2016 Dec 14;8(369):369ra175.

12.

Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer.

Pollock JA, Wardell SE, Parent AA, Stagg DB, Ellison SJ, Alley HM, Chao CA, Lawrence SA, Stice JP, Spasojevic I, Baker JG, Kim SH, McDonnell DP, Katzenellenbogen JA, Norris JD.

Nat Chem Biol. 2016 Oct;12(10):795-801. doi: 10.1038/nchembio.2131. Epub 2016 Aug 8.

13.

Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader.

Wardell SE, Nelson ER, Chao CA, Alley HM, McDonnell DP.

Endocr Relat Cancer. 2015 Oct;22(5):713-24. doi: 10.1530/ERC-15-0287. Epub 2015 Jul 10.

14.

Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer.

McDonnell DP, Wardell SE, Norris JD.

J Med Chem. 2015 Jun 25;58(12):4883-7. doi: 10.1021/acs.jmedchem.5b00760. Epub 2015 Jun 3.

15.

Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.

Wardell SE, Ellis MJ, Alley HM, Eisele K, VanArsdale T, Dann SG, Arndt KT, Primeau T, Griffin E, Shao J, Crowder R, Lai JP, Norris JD, McDonnell DP, Li S.

Clin Cancer Res. 2015 Nov 15;21(22):5121-5130. doi: 10.1158/1078-0432.CCR-15-0360. Epub 2015 May 19.

16.

Systematic identification of signaling pathways with potential to confer anticancer drug resistance.

Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff M, Chen PL, Rathmell JC, Flaherty KT, Wargo JA, McDonnell DP, Sabatini DM, Wood KC.

Sci Signal. 2014 Dec 23;7(357):ra121. doi: 10.1126/scisignal.aaa1877.

17.

Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.

Wright TM, Wardell SE, Jasper JS, Stice JP, Safi R, Nelson ER, McDonnell DP.

Mol Cancer Res. 2014 Dec;12(12):1829-39. doi: 10.1158/1541-7786.MCR-14-0195. Epub 2014 Aug 6.

18.

From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs).

Wardell SE, Nelson ER, McDonnell DP.

Steroids. 2014 Nov;90:30-8. doi: 10.1016/j.steroids.2014.07.013. Epub 2014 Jul 30.

19.

Obesity, cholesterol metabolism, and breast cancer pathogenesis.

McDonnell DP, Park S, Goulet MT, Jasper J, Wardell SE, Chang CY, Norris JD, Guyton JR, Nelson ER.

Cancer Res. 2014 Sep 15;74(18):4976-82. doi: 10.1158/0008-5472.CAN-14-1756. Epub 2014 Jul 24.

20.

27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology.

Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V, Umetani M, Geradts J, McDonnell DP.

Science. 2013 Nov 29;342(6162):1094-8. doi: 10.1126/science.1241908.

21.

Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease.

Wardell SE, Nelson ER, Chao CA, McDonnell DP.

Clin Cancer Res. 2013 May 1;19(9):2420-31. doi: 10.1158/1078-0432.CCR-12-3771. Epub 2013 Mar 27.

22.

The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis.

Nelson ER, Wardell SE, McDonnell DP.

Bone. 2013 Mar;53(1):42-50. doi: 10.1016/j.bone.2012.11.011. Epub 2012 Nov 17. Review.

23.
24.

The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy.

Wardell SE, Marks JR, McDonnell DP.

Biochem Pharmacol. 2011 Jul 15;82(2):122-30. doi: 10.1016/j.bcp.2011.03.031. Epub 2011 Apr 9.

25.

The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.

McDonnell DP, Wardell SE.

Curr Opin Pharmacol. 2010 Dec;10(6):620-8. doi: 10.1016/j.coph.2010.09.007. Review.

26.

Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain coactivator and phosphorylation of serine400.

Wardell SE, Narayanan R, Weigel NL, Edwards DP.

Mol Endocrinol. 2010 Feb;24(2):335-45. doi: 10.1210/me.2008-0081. Epub 2009 Dec 11.

27.

Glucose metabolism as a target of histone deacetylase inhibitors.

Wardell SE, Ilkayeva OR, Wieman HL, Frigo DE, Rathmell JC, Newgard CB, McDonnell DP.

Mol Endocrinol. 2009 Mar;23(3):388-401. doi: 10.1210/me.2008-0179. Epub 2008 Dec 23.

28.

International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors.

Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V, Hochberg RB, McKay L, Renoir JM, Weigel NL, Wilson EM, McDonnell DP, Cidlowski JA.

Pharmacol Rev. 2006 Dec;58(4):782-97. Review. No abstract available.

PMID:
17132855
29.
30.

Mechanisms controlling agonist and antagonist potential of selective progesterone receptor modulators (SPRMs).

Wardell SE, Edwards DP.

Semin Reprod Med. 2005 Feb;23(1):9-21. Review.

PMID:
15714386
31.

Progesterone receptor interacting coregulatory proteins and cross talk with cell signaling pathways.

Edwards DP, Wardell SE, Boonyaratanakornkit V.

J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):173-86.

PMID:
12650714
32.

Jun dimerization protein 2 functions as a progesterone receptor N-terminal domain coactivator.

Wardell SE, Boonyaratanakornkit V, Adelman JS, Aronheim A, Edwards DP.

Mol Cell Biol. 2002 Aug;22(15):5451-66.

Supplemental Content

Loading ...
Support Center